key: cord-0832183-gij1kdrv
authors: Dodd, Roger Y; Spencer, Bryan R; Meng, Xu; Foster, Gregory A; Saa, Paula; Brodsky, Jaye P; Stramer, Susan L
title: Characteristics of US Blood donors testing reactive for antibodies to SARS-CoV-2 prior to the availability of authorized vaccines
date: 2021-07-30
journal: Transfus Med Rev
DOI: 10.1016/j.tmrv.2021.07.001
sha: 670390fa135ef0a17df07418e7cdb6c1af07e832
doc_id: 832183
cord_uid: gij1kdrv

In the United States, many blood collection organizations initiated programs to test all blood donors for antibodies to SARS-CoV-2, as a measure to increase donations and to assist in the identification of potential donors of COVID-19 convalescent plasma (CCP). As a result, it was possible to investigate the characteristics of healthy blood donors who had previously been infected with SARS-CoV-2. We report the findings from all blood donations collected by the American Red Cross, representing 40% of the national blood supply covering 44 States, in order to characterize the seroepidemiology of SARS-CoV-2 infection among blood donors in the United States, prior to authorized vaccine availability. We performed an observational cohort study from June 15(th) to November 30(th), 2020 on a population of 1.531 million blood donors tested for antibodies to the S1 spike antigen of SARS-CoV-2 by person, place, time, ABO group and dynamics of test reactivity, with additional information from a survey of a subset of those with reactive test results. The overall seroreactivity was 4.22% increasing from 1.18 to 9.67% (June-Nov 2020); estimated incidence was 11.6 per hundred person-years, 1.86-times higher than that based upon reported cases in the general population over the same period. In multivariable analyses, seroreactivity was highest in the Midwest (5.21%), followed by the South (4.43%), West (3.43%) and Northeast (2.90%). Seroreactivity was highest among donors aged 18-24 (Odds Ratio 3.02 [95% Confidence Interval 2.80-3.26] vs age >55), African-Americans and Hispanics (1.50 [1.24-1.80] and 2.12 [1.89-2.36], respectively, vs Caucasian). Group O frequency was 51.5% among nonreactive, but 46.1% among seroreactive donors (p<0.0001). Of surveyed donors, 45% reported no COVID-19-related symptoms, but 73% among those unaware of testing. Signal levels of antibody tests were stable over 120 days or more and there was little evidence of reinfection. Evaluation of a large population of healthy, voluntary blood donors provided evidence of widespread and increasing SARS-CoV-2 seroprevalence and demonstrated that at least 45% of those previously infected were asymptomatic. Epidemiologic findings were similar to those among clinically reported cases.

Despite the extent of the COVID-19 pandemic in the United States, there has been limited information about the overall seroprevalence and the frequency of recognized asymptomatic infection. Although blood donors are not fully representative of the US population, they provide a healthy subset with more than 10 million samples per year. [1] Large-scale testing for antibodies to SARS-CoV-2 has been implemented by many US blood collection organizations, offering an opportunity to examine these issues. An early analysis indicated that the demographics and regional distribution of seroreactivity were similar to national data on COVID-19. [2] Also, evaluation of data from retained samples from donors suggested the presence of SARS-CoV-2 earlier than the generally recognized date of first appearance of the virus in the US. [3] We report on the frequency of reactivity using a specific spike antibody test for SARS-CoV-2, validated by using an alternate test directed to a different viral target, by person, place, time and blood type within the American Red Cross (ARC) donor population. We report the frequency of asymptomatic infections, infection incidence relative to clinical case findings, the dynamics of antibody levels post-infection, self-reported symptoms, and test awareness.

Combined data for these attributes in a large segment the US population have not been reported previously in a single defined study.

The ARC collects about 40% of the US blood supply from 44 states and has tested every donor for antibodies to SARS-CoV-2 since June 15, 2020 using the Ortho VITROS anti-SARS-CoV-2 S1

Total Ig assay (identified as the Ortho test) (Raritan NJ). [2, 4] Descriptive studies were conducted for 1,531,221 donors who made 2,191,731 million donations of whole blood, double red-cells or single-donor platelets between June 15 th and November 30 th , 2020, before the general availability of SARS-CoV-2 vaccines in the US; donors of COVID-19 convalescent plasma were excluded. On average, each donor gave 1.43 donations. Donors with any donation having a reactive test result (signal-to-cutoff [S/CO] ratio  1.00) were defined as seroreactive.

Information from the donation record included donor status (first-time or repeat), sex, age, self-identified race/ethnicity, location of residence and ABO Group. Studies on changes in donors' antibody signal strength over time were conducted on the subset of donors with multiple test-reactive donations or those who seroconverted. Testing and data collection were considered by the ARC's Institutional Review Board (IRB) to be exempt as human subjects' research; each donor was provided with an information sheet prior to agreeing to donate. 

A survey of donors with seroreactive test results was conducted to understand their history of COVID-19 diagnosis, prior testing, disease symptoms and motivation for donation in the context of COVID-19 testing. Eligibility for the web-based questionnaire was based on blood donation during the study period. The survey was voluntary and approved by the ARC IRB without requirement for written or verbal consent. Survey exclusion criteria were applied to 64,633 seroreactive donors, removing 22% without an e-mail address, 20% requesting no e-mail contact, 3% less than 18 years old, and fewer than 2% Spanish-speaking, having incorrect e-mail addresses, or previously opting out of research. For each symptom, "yes" or "no" responses were recorded, but those identified as "Unsure" were omitted. The Supplement contains the survey instrument.

Analyses of donor characteristics were reported at the level of individual donors. Donor characteristics associated with seroreactivity, including age, sex, race/ethnicity, region of residence, and ABO blood group were assessed using bivariable and multivariable logistic regression. In analyses of temporal change in antibody signal strength in donors with repeated donations, data were assessed by Spearman rank correlation and Kruskal-Wallis test. Within that population, the 469,605 donors who gave more than once provided 1.13 million donations, or 2.41 per donor. For surveyed donors, comparison of mean counts of symptoms (maximum of 12) by co-morbidity was performed using Wilcoxon rank sum test, with Bonferroni correction for multiple comparisons. We conducted all analyses using SAS software (version 9.4, SAS Institute Inc., Cary NC). P values of less than 0.05 were considered significant. Relevant evaluations were 2-sided.

Of 1,531,221 donors, 64,633 (4.22%) had one or more seroreactive results. Among the seroreactive donors, 56,397 (87.25%) were also tested by Roche; 51,335 (91.02%) were Rochereactive. Supplemental Table 1 shows the distribution of Roche-reactive samples. Of note, Roche nonreactive signals span the entire nonreactive dynamic range and do not correlate with seroreactive (Ortho) signal levels (Supplemental Figure 1) . Thus, we are not able to establish that seroreactive, Roche nonreactive results are falsely positive, and because the frequency of Roche reactivity was stable over time, we focused primarily on seroreactive results knowing that over 90% were concordantly reactive by both tests. donations/donor for reactives, and 1.44 donations/donor for nonreactives); thus, data by donation differ from the donor-based data in Table 1 . The frequency of ABO groups differed between nonreactive and seroreactive donors. Relative to Group O, Groups A, AB and B were seen more frequently among seroreactive donors, (p<0.0001 in both bivariable and multivariable analyses; Table 1 ), to a somewhat lesser degree for Group B, but still highly significant. The odds ratios for seroreactivity among A, AB, and B, relative to Group O were 1.32 (95% CI, 1.25-1.38), 1.26 (95% CI, 1.12-1.41) and 1.16 (95% CI, 1.08-1.25). Group O frequency was 51.5% among nonreactives but 46.1% among seroreactive donors (p<0.0001).

Within the population of 1,531,221 donors, 469,605 gave blood twice or more, for a total of Figure 3A shows the mean and median log 10 S/CO values for the antibody test signals by time between seroreactive donations (i.e., for donors whose donation remained reactive during the entire study period); overall, the test signals increased significantly over time from the first seroreactive donation (p<0.0001). Further examination of the trajectory of signal levels by individual donor showed that 590 donors had a signal reduction of greater than 0.1 log 10 , while 1,721 had stable levels within plus or minus 0.1 log 10 with the majority of 6,272 having a signal increase of greater than 0.1 log 10 ( Figures 3B-D 

A total of 35,198 (54.5%) seroreactive donors were invited to participate in the survey, with 13,343 (37.9%) responding. Of those, 45% reported no symptoms of the 12 surveyed, for the period of 14 or more days before donation; no significant difference in S/CO values was observed between asymptomatic and symptomatic donors (S/CO mean 127 and 121, respectively). Among those reporting symptoms, the average number reported was 5.0.

Subjects reporting a medical diagnosis of COVID-19 reported more symptoms than those without a diagnosis (an average of 4.2 and 2.1, respectively). Among those with symptoms, fatigue was most frequent (40%), followed by headache (33%), myalgia (32%), and loss of smell (28%); fever was reported by only 19% (Figure 4) 

Despite the lack of evidence that SARS-CoV-2 is transmissible by blood transfusion, [7, 8] the pandemic has had a profound impact on the collection and distribution of blood for transfusion.

Testing blood donors for SARS-CoV-2 antibodies was implemented in part to encourage donation and to support the need for convalescent plasma. Seroreactivity is more frequent among first-time donors than routine, or repeat donors (Table   1 ). It seems likely that this is related to the availability of the test, particularly among those who were concerned about potential exposure, or prior symptoms. It is well-known that the prevalence of markers for transfusion-transmissible agents is lower among repeat donors, but this is in part because individuals who test reactive are deferred from further donation. [9] This is not the case for COVID-related antibody tests as donors with reactive antibody-test results may continue to donate.

As reported previously, the frequency of seroreactivity varies significantly by age, race/ethnicity and location. [2] Noticeably however, in a multivariable analysis the impact of age is greater than reported earlier, while the impact of race and ethnicity is less apparent, although African-American and Hispanic donors continue to be at significantly greater risk than are Caucasian donors.

may be associated with a higher risk of infection and severe disease. [10] The odds ratios for seroreactivity among A, AB, and B, relative to Group O were respectively 1.32, 1.26 and 1.16 and all were significant (p<0.0001; Table 1 ). In fact, the percentage of Group O donors among test-nonreactive donors was 51.5%, while among seroreactive donors, was 46.1%, supporting a lower rate of infection in those donors with Group O red cells. Also, the lower odds ratio for Group B as compared to Groups A and AB further supports the concept that the effect is likely attributable to the natural antibody response to the A antigen, which can be expressed on the SARS-CoV-2 virion. [11] In this study, we found that the signal levels of the antibody tests used were remarkably stable over a period of 120 days or more. The overall trend was towards an increase in signals with only a few (590 of 8,583, 6.9%) showing a downward trend; other reports have shown stable antibody profiles for 4-6 months. [12] [13] [14] [15] [16] Examination of individual signal-level profiles among those with three or more seroreactive donations suggests that large increases in signal levels were rare or absent, and thus, that reinfection was infrequent among those individuals. [15, 16] Greater duration of antibody detectability has been observed with tests that use a total immunoglobin format (direct antigen sandwich) versus those with an IgG format (second antibody detection) as true of the tests used in our study. [16] This likely contributed to the sustained antibody response that we observed.

A notable proportion (45%) of surveyed, seroreactive donors were asymptomatic. This figure may not be representative of the general population, as most seroreactive respondents reported a history of diagnosis or contact with COVID-19 or indicated that they were aware that they would be tested. In this context, it is of interest to note that about 73% of individuals who reported that they were unaware of the testing, and were not motivated by test availability, reported no symptoms compared to 48% in The Netherlands. [17] Most of these asymptomatic donors were reactive by both the Ortho and Roche tests (79%). Thus, a measurable proportion of the population has unknowingly been infected with SARS-CoV-2. [18, 19] The dynamics of the blood donor population who test reactive for SARS-CoV-2 antibodies is changing with the availability of vaccination and consequently patterns of test reactivity will reflect the mixture of donors with natural and vaccine-induced seropositivity. In fact, in the six months following vaccine availability, over 80% of seroreactive donors acknowledged vaccination with antibody reactivity consistent with vaccination (nucleocapsid nonreactive).

This contrasts with 9% having isolated seroreactivity prior to vaccine availability.

The COVID-19 pandemic affected different populations and countries differently and varied over time with second waves following the summer of 2020. The overall 4.22% seroprevalence documented for the US blood donor population in this study from June to November 2020 was consistent with other studies; it rose significantly from 1.18% to 9.67% by the last reporting period. For example, of eight studies in blood donors published in Europe, [20] seroprevalence ranged from 0.91% in North-Western Germany to 23.3% in a high-transmission area in the Lombardy region, Italy. In the UK, seroprevalence rates of 4.9% occurred after the first epidemic wave (June-Sept 2020), and similar to our study, found the highest prevalence in younger versus older individuals. [21] Declines in seroprevalence were documented, particularly for those 75 years or older and those who did not report a history of symptomatic infection (presumably asymptomatic infection) as a function of antibody waning. In our study, that used a robust total immunoglobulin test directed towards S1, no antibody waning was observed over 4 months. Antibody testing of ~50,000 blood donations from six US 

The study does have some limitations. The data presented are based upon a single test without a formal confirmatory test or any repeat testing. A second (Roche) test was reactive among 91% of seroreactive donors (Supplemental Table 1 ), and it is probable that the Ortho test may be slightly more sensitive than the Roche test, possibly due to the selection of a spike versus nucleocapsid target, respectively. [11] This was seen in the large number of elevated, but nonreactive Roche results in seroreactive donors (Supplemental Figure 1) , and by the greater increase in signal strength observed over time for Ortho versus Roche reactive donors ( Figure 3 and Supplemental Figure 4A ). In the absence of a gold-standard confirmatory test, we elected to present seroprevalence data based upon reactivity by the Ortho test.

The blood donor population is not representative of the population as a whole; at any time, approximately 3% donate.

[23] We do, however, note that the observed trends relating to age, race/ethnicity and location of seroreactive donors follow national trends for COVID-19. [18, 24] Survey data show that most donors were aware that antibody testing was available and that some (particularly first-time donors) were motivated to give blood, thus impacting the extent to which our data are broadly representative. However, the response to the survey instrument represents a relatively small proportion of all donors: only 13,343 of 64,633 (20.6%). Figure 3B shows donors with donation decreases of > 0.1 log 10 , Figure 3C shows donors with donation changes within the range of  0.1 log 10 and Figure 3D shows donors with donation increases of > 0.1 log 10 . The 

Slowing decline in blood collection and transfusion in the United States -2017

Change in donor characteristics and antibodies to SARS-CoV-2 in donated blood in the US

Serologic testing of US blood donations to identify SARS-CoV-2 reactive Antibodies

Instructions for use: Ortho VITROS Immunodiagnostic Products Anti-SARDS-CoV-2 Total Reactions Pack

Roche cobas Elecsys Anti-SARS-CoV-2 System

Is SARS-CoV-2 transfusion transmitted?

Minipool testing for SARS-CoV-2 RNA in United States blood donors

Screening blood donors for HIV, HCV, and HBV at the American Red Cross: 10-year trends in prevalence, incidence, and residual risk

ABO blood Group and COVID-19: a review on behalf of the ISBT COVID19 working Group. Vox Sang

Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2

Orthogonal SARS-CoV-2 serological assays enable surveillance of low prevalence communities and reveal durable humoral Immunity

Evolution of antibody immunity to SARS-CoV-2

Persistence of SARS-CoV-2 N-antibody response in healthcare workers

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Humoral immune response to SARS-CoV-2 in Iceland

Low awareness of past SARS-CoV-2 infection in healthy plasma donors

Estimated incidence of Coronavirus Disease 2019 (COVID-19) illness and hospitalization-United States

SARS-CoV-2 transmission from people without COVID-19 symptoms

SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review

Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults

Use of US blood donors for national serosurveillance of SARS-CoV-2 antibodies: Basis for an expanded national serosurveillance program

Estimated SARS-CoV-2 seroprevalence in the US as of

We thank the many employees of the American Red Cross who contributed to this study, including Laura Tonnetti, PhD, and Jamel Groves, MS, of Scientific Affairs for protocol and data management, David Krysztof for administrative and project management support, and the case investigators at Scientific Affairs and the Donor and Client Support Center. We thank the laboratory staff at the American Red Cross Scientific Support Office within Scientific Affairs and Creative Testing Solutions for their assistance with donor testing including supplemental testing. Funding for antibody testing was provided in part by the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergies and Infectious Diseases (NIAID), NIH (24,999 donations, June-August 2020; NHLBI Contracts HHSN 75N92019D00032 and HHSN 75N92019D00033) and the Centers for Disease Control and Prevention (358,000 donations, July-November 2020; CDC contract number 75D30120C08170).

The authors report no relevant conflict of interest.